Page 62 - Read Online

48. Pyronnet S, Bousquet C, Najib S, Azar R, Laklai H, Susini P, Croce CM, Scarpa A. Pancreatic endocrine tumours: expression
C. Antitumour effects of somatostatin. Mol Cell Endocrinol profiling evidences a role for AKT-mTOR pathway. J Clin Oncol
2008;286:230-7. 2010;28:245-55.
49. Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, 62. Humar R, Kiefer FN, Berns H, Resink TJ, Battegay EJ. Hypoxia
Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, Harder enhances vascular cell proliferation and angiogenesis in vitro via
J, Arnold C, Gress T, Arnold R; PROMID Study Group. Placebo- rapamycin (mTOR)-dependent signalling. FASEB J 2002;16:771-80.
controlled, double-blind, prospective, randomized study on the 63. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation.
effect of octreotide LAR in the control of tumour growth in patients Cell 2011;144:646-74.
with metastatic neuroendocrine midgut tumours: a report from the 64. Yao JC, Lombard-Bohas C, Baudin E Kvols LK, Rougier P,
PROMID Study Group. J Clin Oncol 2009;27:4656-63. Ruszniewski P, Hoosen S, St Peter J, Haas T, Lebwohl D, Van
50. Caplin ME, Pavel M, Ćwikla JB, Phan AT, Raderer M, Sedláčková Cutsem E, Kulke MH, Hobday TJ, O’Dorisio TM, Shah MH, Cadiot
E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, G, Luppi G, Posey JA, Wiedenmann B. Daily oral everolimus
Martinez S, Blumberg J, Ruszniewski P; CLARINET Investigators. activity in patients with metastatic pancreatic neuroendocrine
Lanreotide in metastatic enteropancreatic neuroendocrine tumours. tumours after failure of cytotoxic chemotherapy: a phase II trial. J
N Engl J Med 2014;371:224-33. Clin Oncol 2010;28:69-76.
51. Arnold R, Wittenberg M, Rinke A, Schade-Brittinger C, 65. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E,
Aminossadati B, Ronicke Gress TM, Mueller HH; PROMID Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti
Study Group; Philipps University Marburg, Department of Internal P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K;
Medicine, Division of Gastroenterology and Endocrinology, RAD001 in Advanced Neuroendocrine Tumors, Third Trial
Marburg, Germany; KKS Marburg, Marburg, Germany; Philipps (RADIANT-3) Study Group. Everolimus for advanced pancreatic
University Marburg; Deptartment of Gastroenterology, Marburg, neuroendocrine tumours. N Engl J Med 2011;364:514-23.
Germany; Koordinierungszentrum für Klinische Studien der 66. Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler
Philipps-Universität Marburg, Marburg, Germany; Institute of RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM, Oberg K, Van
Medical Informatics, Biometry and Epidemiology, LMU Munich, Cutsem E, Yao JC; RADIANT-2 Study Group. Everolimus plus
München, Germany. PROMID Study Group. Placebo controlled, octreotide long-acting repeatable for the treatment of advanced
double blind, prospective, randomized study on the effect of neuroendocrine tumours associated with carcinoid syndrome
octreotide LAR in the control of tumour growth in patients with (RADIANT- 2): a randomised, placebo-controlled, phase 3 study.
metastatic neuroendocrine midgut tumours (PROMID): results on Lancet 2011;378:2005-12.
long-term survival. ASCO 2013;31:Abstr 4030. 67. Fazio N, Granberg D, Grossman A, Saletan S, Klimovsky J,
52. Schmid HA. Pasireotide (SOM230): development, mechanism Panneerselvam A, Wolin EM. Everolimus plus octreotide long-
of action and potential applications. Mol Cell Endocrinol acting repeatable in patients with advanced lung neuroendocrine
2008;286:69-74. tumors: analysis of the phase 3, randomized, placebo-controlled
53. Wolin EM, Jarzab B, Eriksson B, Walter T, Toumpanakis C, Morse RADIANT-2 study. Chest 2013;143:955-62.
MA, Tomassetti P, Weber MM, Fogelman DR, Ramage J, Poon D, 68. Duran I, Kortmansky J, Singh D, Hirte H, Kocha W, Goss G,
Gadbaw B, Li J, Pasieka JL, Mahamat A, Swahn F, Newell-Price J, Le L, Oza A, Nicklee T, Ho J, Birle D, Pond GR, Arboine D,
Mansoor W, Öberg K. A multicenter, randomized, blinded, phase Dancey J, Aviel-Ronen S, Tsao MS, Hedley D, Siu LL. A phase II
III study of pasireotide LAR versus octreotide LAR in patients with clinical and pharmacodynamic study of temsirolimus in advanced
metastatic neuroendocrine tumours (NET) with disease-related neuroendocrine carcinomas. Br J Cancer 2006;95:1148-54.
symptoms inadequately controlled by somatostatin analogs. J Clin 69. Hafsi S, Pezzino FM, Candido S, Ligresti G, Spandidos DA, Soua
Oncol 2013;31:abstr s4031. Z, McCubrey JA, Travali S, Libra M. Gene alterations in the PI3K/
54. Kulke MH, O’Dorisio T, Phan A, Bergsland E, Law L, Banks P, PTEN/AKT pathway as a mechanism of drug-resistance (review).
Freiman J, Frazier K, Jackson J, Yao JC, Kvols L, Lapuerta P, Int J Oncol 2012;40:639-44.
Zambrowicz B, Fleming D, Sands A. Telotristat etiprate, a novel 70. Zhang S, Yu D. PI(3)king apart PTEN’s role in cancer. Clin Cancer
serotonin synthesis inhibitor, in patients with carcinoid syndrome Res 2010;16:4325-30.
and diarrhea not adequately controlled by octreotide. Endocr Relat 71. Ramaswamy S, Nakamura N, Vazquez F, Batt DB, Perera S, Roberts
Cancer 2014;21:705-14. TM, Sellers WR. Regulation of G1 progression by the PTEN tumour
55. Pavel M, Hörsch D, Caplin M, Ramage J, Seufferlein T, Valle suppressor protein is linked to inhibition of the phosphatidylinositol
J, Banks P, Lapuerta P, Sands A, Zambrowicz B, Fleming D, 3-kinase/Akt pathway. Proc Natl Acad Sci U S A 1999;96:2110-5.
Wiedenmann B. Telotristat etiprate for carcinoid syndrome: a single- 72. Myers MP, Pass I, Batty IH, Van der Kaay J, Stolarov JP, Hemmings
arm, multicenter trial. J Clin Endocrinol Metab 2015;100:1511-9. BA, Wigler MH, Downes CP, Tonks NK. The lipid phosphatase
56. Aparicio T, Ducreux M, Baudin E, Sabourin JC, De Baere T, Mitry activity of PTEN is critical for its tumour suppressor function. Proc
E, Schlumberger M, Rougier P. Antitumour activity of somatostatin Natl Acad Sci U S A 1998;95:13513-8.
analogues in progressive metastatic neuroendocrine tumours. Eur J 73. Furnari FB, Huang HJ, Cavenee WK. The phosphoinositol
Cancer 2001;37:1014-9. phosphatase activity of PTEN mediates a serum-sensitive G1
57. Filosso PL, Ruffini E, Oliaro A, Papalia E, Donati G, Rena O. Long- growth arrest in glioma cells. Cancer Res1998;58:5002-8.
term survival of atypical bronchial carcinoids with liver metastases, 74. Putz U, Howitt J, Doan A, Goh CP, Low LH, Silke J, Tan SS.
treated with octreotide. Eur J Cardiothorac Surg 2002;21:913-7. The tumour suppressor PTEN is exported in exosomes and has
58. Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer phosphatase activity in recipient cells. Sci Signal 2012;5:ra70.
Cell 2005;8:179-83. 75. Tamura M, Gu J, Takino T, Yamada KM. Tumour suppressor PTEN
59. Alonso-Gordoa T, Capdevila J, Grande E. GEP-NETs Update: inhibition of cell invasion, migration, and growth: differential
Biotherapy for neuroendocrine tumours. Eur J Endocrinol involvement of focal adhesion kinase and p130Cas. Cancer Res
2015;172:R31-46. 1999;59:442-9.
60. Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, Schulick 76. Kim JS, Xu X, Li H, Solomon D, Lane WS, Jin T, Waldman T.
RD, Tang LH, Wolfgang CL, Choti MA, Velculescu VE, Diaz LA Jr, Mechanistic analysis of a DNA damage-induced, PTEN-dependent
Vogelstein B, Kinzler KW, Hruban RH, Papadopoulos N. DAXX/ size checkpoint in human cells. Mol Cell Biol 2011;31:2756-71.
ATRX, MEN1, and mTOR pathway genes are frequently altered in 77. Wang L, Ignat A, Axiotis CA. Differential expression of the PTEN
pancreatic neuroendocrine tumours. Science 2011;331:1199-203. tumour suppressor protein in fetal and adult neuroendocrine tissues
61. Missiaglia E, Dalai I, Barbi S, Beghelli S, Falconi M, della Peruta and tumours: progressive loss of PTEN expression in poorly
M, Piemonti L, Capurso G, Di Florio A, delle Fave G, Pederzoli differentiated neuroendocrine neoplasms. Appl Immunohistochem
338
Journal of Cancer Metastasis and Treatment ¦ Volume 2 ¦ August 31, 2016 ¦